145576-26-7 Usage
Description
Simvastatin Hydroxy Acid Methyl Ester is an organic compound derived from the hydrolysis of Simvastatin, a widely used cholesterol-lowering drug. It is characterized by its clear, colorless, and thick oily appearance. Simvastatin Hydroxy Acid Methyl Ester is primarily known as an impurity in Simvastatin tablets, which are used for the treatment of high cholesterol and related cardiovascular conditions.
Uses
Used in Pharmaceutical Industry:
Simvastatin Hydroxy Acid Methyl Ester is used as an impurity in the production of Simvastatin (S485000) tablets for the treatment of high cholesterol. Its presence, although as an impurity, is significant in the overall formulation and effectiveness of the drug. The compound contributes to the pharmacological action of the medication by potentially enhancing the cholesterol-lowering properties of the main active ingredient.
As an impurity, Simvastatin Hydroxy Acid Methyl Ester may also play a role in the stability, solubility, or absorption of the drug, although its specific contribution to these aspects is not explicitly mentioned in the provided materials. Further research and analysis would be required to determine the exact impact of this compound on the overall performance and safety of Simvastatin tablets.
Check Digit Verification of cas no
The CAS Registry Mumber 145576-26-7 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,4,5,5,7 and 6 respectively; the second part has 2 digits, 2 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 145576-26:
(8*1)+(7*4)+(6*5)+(5*5)+(4*7)+(3*6)+(2*2)+(1*6)=147
147 % 10 = 7
So 145576-26-7 is a valid CAS Registry Number.
145576-26-7Relevant articles and documents
Tumor Homing Statin Derivatives
-
Paragraph 0245-0247, (2021/01/25)
The present invention generally relates to tumor homing statin derivatives (THSD) and their use for therapy, in particular cancer therapy. These THSD comprise three moieties: a statin moiety which comprises a dihydroxyheptanoic acid unit (DHHA) fixated by linkage into its open chain form, a heptamethine carbocyanine dye (HMCD) moiety, and a linker that conjugates the DHHA of the statin to the dye moiety. The linker is linked to the DHHA via an ester bond (ester-linked statin derivative or ELSD), or via an amide bond (amide-linked statin derivative or ALSD). Thus linked to the DHHA, the linker provides a relatively stable link either for essentially no hydrolysis/statin release after administration, or preferably for very slow hydrolysis and statin release, as is the case for the ELSD. Embodiments include methods to provide the desired THSD, in particular the ELSD, with the DHHA in its open chain form. The invention also relates to methods wherein one or more ELSD is administered to a patient in a therapeutically effective amount, and methods wherein an ELSD and an ALSD are co-administered in a coordinated administration schedule. Advantages of the THSD and their use include, among others, improved efficacy and dose-response, and decreased statin-associated side effects.
METHODS FOR MAKING SIMVASTATIN AND INTERMEDIATES
-
Page/Page column 73-74, (2008/06/13)
The invention provides synthetic chemical and chemoenzymatic methods of producing simvastatin and various intermediates. In one aspect, enzymes such as hydrolases, e.g., esterases, are used in the methods of the invention.
